#Neladalkib: A Fourth Generation TKI.

#LungCancerTreatment #TargetedTherapies #ALK #TKI

Isabel Preeshagul

#TargetedTherapies #LungCancer #LungCancerTreatment

Gut bacteria molecule boosts lung cancer immunotherapy – BioNews Central Researchers have discovered a small compound produced naturally by gut bacteria that doubled the response to lung cancer immunotherapy in mice and can now be made into a drug for testing in humans. ...

Researchers have discovered a #SmallMolecule produced naturally by #GutBacteria that doubled the response to #LungCancer #immunotherapy in mice and can now be made into a #drug for testing in humans.
#LungCancerTreatment #CombinationTherapy #MicrobialMetabolite

Advanced Lung Cancer Treatment in #Varanasi: Understanding the Causes, Key Symptoms, and Modern Care Options tinyurl.com/53ku424c

#LungCancerTreatment #SwapnilPatel #CancerSurgeon

💊 Glecirasib Citrate Tablets—now approved in China!
🎯 Targets KRAS G12C–mutated advanced NSCLC

📎 Learn more: dengyuemed.com/product/airu...
📧 info@dengyuemed.com

#GlecirasibCitrateTablets #Allist #KRASG12C #KRAS #KRASInhibitor #NSCLC #LungCancerTreatment
#HongKongDengYueMedicine

Lung cancer is the leading killer in Nebraska. In 2025, state projections estimate 1,260 new diagnoses and 720 deaths due to the disease. CHI Health

buff.ly/rZYRSdA

#MED #CHIHealth #LungCancerScreening #LungCancerTreatment

FDA grants accelerated approval to datopotamab deruxtecan-dlnk On June 23, 2025, the Food and Drug Administration granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.).

FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer.

Learn more ➡️ bit.ly/44fIz4B

#FDAApproval #AcceleratedApproval #OncologyNews
#LungCancerTreatment #CancerResearch

Lurbinectedin with atezolizumab maintenance therapy in extensive-stage small-cell lung cancer Small-cell lung cancer (SCLC) is one of the most lethal cancers, with patients diagnosed with extensive-stage small-cell lung cancer (ES-SCLC) experiencing a median survival of just 12 months after st...

Drs. Choudhury & Garassino have a great new paper out in The Lancet about the importance of the maintenance phase of treatment in extensive-stage small-cell lung cancer! You can read it at www.thelancet.com/journals/lan...

#lungcancer #lungcancertreatment #OncSky

Immunotherapy before surgery improves lung cancer survival – BioNews Central Results from a phase 3 clinical trial show that combining immunotherapy with chemotherapy before lung cancer surgery lowers the risk of cancer recurrence and increases long-term survival. ...

Results from a phase 3 #ClinicalTrial show that combining #immunotherapy with #chemotherapy before #LungCancerSurgery lowers the risk of #CancerRecurrence and increases long-term #survival. 
#NonSmallCellLungCancer #NSCLC #LungCancerTreatment

“We have the ability to travel further into the lungs than ever before... The kind of detail we can see now enables us to identify small tumors when they are most treatable.” More at www.sjchs.org/smart-living...
#lungcancer #cancer #cancercenter #lungcancertreatment #oncology

Amivantamab plus lazertinib shows survival benefit in lung cancer - PharmaTimes Janssen drug combination extends life expectancy during trial

#oncology #Amivantamab #lazertinib #lungcancer #Janssen #phase3clinicaltrial #MARIPOSAstudy #EGFRmutatedadvancednonsmallcelllungcancer #NSCLC #nonsmallcelllungcancer #Rybrevant #Lazcluze #EuropeanLungCancerCongress #lungcancertreatment #patientoutcomes
pharmatimes.com/news/amivant...

Speakers Bureau member Lysa Buonanno is accessing tomorrow’s treatments today through clinical trials. Learn more about clinical trials in the link: https://buff.ly/40OIa7G

#ClinicalTrials #LungCancerTreatment

Amgen’s lung cancer treatment gets conditional approval - PharmaTimes IMDYLLTRA offers new hope for patients with extensive-stage small cell lung cancer

#oncology #lungcancer @amgen.bsky.social #lungcancertreatment #IMDYLLTRA #tarlatamab #extensivestagesmallcelllungcancer #ESSCLC #ESSCLCpatients #UK #MHRA #conditionalmarketingauthorisation #Smallcelllungcancer #SCLC #DeLLphi301study #objectiveresponserate
pharmatimes.com/news/amgens-...

Imfinzi receives NICE recommendation for lung cancer treatment - PharmaTimes Trial results lead to new treatment option for lung cancer

#oncology #Imfinzi #durvalumab #AstraZeneca #NICErecommendation #lungcancer #lungcancerpatients #lungcancertreatment #resectablenonsmallcelllungcancer #NSCLC #AEGEANphase3trial #NHS #NSCLCpatients #ThoracicOncology #patientoutcomes #AEGEANtrial
pharmatimes.com/news/imfinzi...

肺癌治疗中的获得性耐药 - East Asian LCVL 2024 youtu.be/gFrAC3p97do?... via @YouTube
帕蒂尔博士讨论了肺癌治疗中的获得性耐药问题，以及肿瘤学家希望如何解决这个问题。
For more, please visit cancergrace.org. To join the conversation, visit cancergrace.org/forum.
#LungCancer #MandarinLungCancerVideo #lungcancertreatment